Professor Johan Vansteenkiste, an associate Editor of Annals of Oncology, discusses the recent publication of Felip et al. that reports a study of the intracranial, and extracranial efficacy of lorlatinib, a potent, brain-penetrant, third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI)in ALK-positive NSCLC that progressed on second-generation ALK TKIs.
Felip E et al. Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs. Ann Oncol 2021; 32: https://doi.org/10.1016/j.annonc.2021.02.012
Stinchcombe TE. Lorlatinib in the treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer.  Ann Oncol 2021; 32: https://doi.org/10.1016/j.annonc.2021.03.002

Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive NSCLC

In this Article of the Month podcast Annals of Oncology Editor-in-Chief Tom Powles discusses a first-in-human study of AMG 193 with Dr Jordi Rodon, MD Anderson Cancer Center, Houston, USA. AMG 193 is a first-in-class, novel, MTA-cooperative PRMT5 inhibitor and a highly selective small molecule designed to specifically target MTAP-deleted cancer. In vitro, AMG 193 preferentially inhibited the MTA-bound PRMT5 enzyme in MTAP-null tumor cells. In vivo, AMG 193 inhibited the growth of multiple MTAP-deleted tumor xenograft models.  
For the full article see https://doi.org/10.1016/j.annonc.2024.08.2339

1st-in-human study of AMG 193 in patients with MTAP-deleted solid tumors: results from phase I dose exploration

Professor Florian Lordick discusses his recent editorial in Annals of Oncology that considered the results of theARTIST 2 and CRITICS trials in gastric cancer, both published in the March issue of the journal.
Adjuvant radiotherapy for gastric cancer—end of the road? F. Lordick, M. Nilsson & T. Leong https://doi.org/10.1016/j.annonc.2020.12.006
ORIGINAL ARTICLEAdjuvant chemotherapy is superior to chemoradiation after D2 surgery forgastric cancer in the per-protocol analysis of the randomized CRITICS trial. W. O. de Steur, R. M. van Amelsfoort, H. H. Hartgrink et al. https://doi.org/10.1016/j.annonc.2020.11.004
A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial. S. H. Park, D.H.Lim, T. S. Sohn et al. https://doi.org/10.1016/j.annonc.2020.11.017

Adjuvant radiotherapy for gastric cancer?

ESMO podcasts offer educational and scientific insights for oncology professionals, covering the latest research, clinical trials, and discussions in cancer care. Topics include highlights from Annals of Oncology and ESMO Open, case-based discussions, expert debates, and content by and for Young Oncologists. Available on Spotify and SoundCloud, these podcasts support continuous learning and multi-professional collaboration in oncology.

1st-in-human study of AMG 193 in patients with MTAP-deleted solid tumors: results from phase I dose exploration

ESMO Podcasts

Related tracks